Perspective Therapeutics (NYSE:CATX) Raised to "Strong-Buy" at Lifesci Capital

Perspective Therapeutics (NYSE:CATX - Get Free Report) was upgraded by stock analysts at Lifesci Capital to a "strong-buy" rating in a research report issued on Thursday,Zacks.com reports.

Other analysts have also issued research reports about the stock. Oppenheimer lowered their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating for the company in a report on Friday, November 22nd. Scotiabank began coverage on Perspective Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 target price for the company. Wedbush reiterated an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Friday, January 24th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. Finally, Bank of America lowered shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the company from $24.00 to $5.00 in a report on Monday, November 25th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $15.13.

Perspective Therapeutics Price Performance

Shares of CATX stock traded up $0.16 during trading hours on Thursday, hitting $2.66. 409,264 shares of the company's stock were exchanged, compared to its average volume of 814,835. The stock's 50-day moving average is $3.18 and its 200-day moving average is $7.48. Perspective Therapeutics has a 52 week low of $2.32 and a 52 week high of $19.05.

Remove Ads

Hedge Funds Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CATX. The Manufacturers Life Insurance Company boosted its holdings in shares of Perspective Therapeutics by 8.9% in the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company's stock valued at $274,000 after buying an additional 1,672 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Perspective Therapeutics by 5.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company's stock valued at $783,000 after acquiring an additional 3,211 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Perspective Therapeutics by 7.4% in the 4th quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company's stock worth $163,000 after purchasing an additional 3,529 shares during the period. US Bancorp DE increased its holdings in Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company's stock worth $88,000 after purchasing an additional 3,866 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Perspective Therapeutics by 4.5% in the 4th quarter. Rhumbline Advisers now owns 94,992 shares of the company's stock valued at $303,000 after purchasing an additional 4,075 shares during the period. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.